After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, ...

“Abrupt” reductions in antidepressant treatment “ranging from 20 percent to 50 percent” Increases in psychotropic drug ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

WATERTOWN, Mass. - Neumora Therapeutics , Inc. (NASDAQ: NMRA) shares dropped 6.4% after the clinical-stage biopharmaceutical company announced changes to its ongoing depression drug trials and ...

Psilocybin-assisted psychotherapy significantly improved a range of psychiatric symptoms among people with cancer, according ...

The American Psychiatric Association (APA) named Mark Rapaport, MD, of the University of Utah, as the medical society's next ...

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

Jab for joy? A landmark study of nearly 30,000 patients found that the use of GLP-1 medications, which include Wegovy and ...

There’s a new crew of characters in HBO’s hit series The White Lotus, but people are already obsessing over one in particular ...

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset missed its primary endpoint in a phase 2b trial. SPN-820 failed to improve ...